RCUS Arcus Biosciences Inc

$RCUS The deal: 14,285,715 shares at $17.50, for $250.0M gross. That's the bottom of the range. Here's what it works out to, using the 127.0M shares outstanding: New shares: The deal: 14,285,715 shares at $17.50, for $250.0M gross., or 11.2% more shares. Cash: about $944M after fees, up from $694M. Underwriters' option: they can buy up to 2,142,857 more shares within 30 days. Or 12.9% more shares Closing: expected Oct 23. Discount: 8.4% below today's $19.10 That's a bit deeper than the 6.4% median in the deals like this. Pricing at the low end hints that buyers had the leverage on this deal, and $17.50 is right at the 52-week low of $17.45.

$RCUS Arcus Biosciences, a clinical-stage cancer drugmaker, reported a 14.5-month median PFS for casdatifan plus cabozantinib in 43 second-line kidney cancer patients after 21.3 months median follow-up, the setting of its Phase 3 PEAK-1. Arcus is worth ~$2.82B at $22.14 (16:00 ET Oct 19, 2026), with $775M cash and investments at June 30, 2026. Against: it's interim data from one cohort, and Arcus warns it may not repeat in PEAK-1, which tests the pair vs cabozantinib alone. PEAK-1 enrollment is due to finish by year-end 2026.

$RCUS +9.8% intraday (10:31 ET) — Oct 20: Arcus presented new ARC-20 casdatifan data in kidney cancer: 1L casdatifan + anti-PD-1 12-month PFS 69%; 2L with cabozantinib median PFS 14.5 months and 18-month OS 77%. Phase 3 PEAK-20 start planned by year-end. Daily chart: opened near 21 USD, reversed up to 24.31 USD, now at the 200-day SMA (24.82 USD) and a rising trendline, still below the falling 50-day SMA (26.73 USD). Analysts: mean target 40 USD (Finviz, Oct 20); William Blair initiated at Outperform (Oct 16). Next catalyst: PEAK-20 Phase 3 start, guided by end of 2026 (company). Not investment advice.

$RCUS the first overall survival number for casdatifan given alone in late-line kidney cancer. Patients lived a median **34.7 months**, compared with **21.4 months** for belzutifan, Merck's approved drug of the same type, in its own trial (LITESPARK-005).

$RCUS - a stock offering at 4:22 PM ET It isn't priced yet, so the share count, price, proceeds and exact dilution are still unknown. - Shares outstanding now:127.0 million. - Cash on hand: about $694 million at Sep 30 - Lock-up:60 days for the company, officers and directors. Its other ongoing share sales are paused for 30 days. - Use of the money:mainly to expand and speed up the casdatifan trials. Here's example math, not the real deal size. At $18.50, every $100 million raised means about 5.4 million new shares, or 4.3% more stock. A $300 million deal plus the full 15% option would be about 18.6 million shares, or roughly 14.7% dilution.

50 percent response rate in first line kidney cancer and the room still needed convincing imo $RCUS up about 11 percent to $24.54 off a $22.14 close on ARC 20 casdatifan data. second line combo did 14.5 months median PFS, late line alone did 35 months median survival Phase 3 PEAK 20 starts by year end. that is a backbone story getting louder ngl

$RCUS why does TD Cowen see a +50-100% upside or 60% downside on next week data? Trying to understand what makes this readout so binary

$RCUS next week is one to watch🚀🚀🚀. This week is stealing shares form the weak hands. 😀 Good Luck - you will need it!